Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HSP90 inhibitor
Macbecin I is an ansamycin antibiotic compound that inhibits Hsp90 activity with IC50 value of μM by binding to the ATP-binding site. -
MAPKAPK2(MK2) inhibitor
MK2-IN-1 hydrochloride is a potent and selecitve MAPKAPK2(MK2) inhibitor(IC50=0.11 uM) with a non-ATP competitive binding mode. -
HSP inhibitor
HSP70-IN-1 is a heat shock protein (HSP) inhibitor; inhibits the growth of Kasumi-1 cells with an IC50 of 2.3 μM. -
Hsc70 and Hsp70 inhibitor
Apoptozole (Apoptosis Activator VII) is an inhibitor of the ATPase domain of Hsc70 and Hsp70, with Kds of 0.21 and 0.14?μM, respectively, and can induce apoptosis. -
Hsp90 inhibitor
SNX-5422 Mesylate (PF-04929113 Mesylate), a prodrug of SNX-2112, is an orally active Hsp90 inhibitor, with a Kd of 41 nM, and also induces Her-2 degradation, with an IC50 of 37?nM. -
cell motility and cell invasion inhibitor
KBU2046 is an oral, highly selective inhibitor of cell motility and cell invasion in vitro. KBU2046 binds chaperone heterocomplexes, selectively alters binding of client proteins that regulate motility, and lacks all of the hallmarks of classical HSP90 inhibitors. KBU2046 inhibits cancer metastasis and prolongs life. -
Hsp90 inhibitor
Alvespimycin is a selective Hsp90 inhibitor with a GI50 of 53 nM. -
Hsp90 inhibitor
Retaspimycin is a potent and water-soluble inhibitor of Hsp90, with EC50s of 119 nM for both Hsp90 and Grp9. -
HSP90β Inhibitor
CCT018159 is an ATP-competitive inhibitor of the HSP90β protein, exhibiting an IC50 of 3.2 μM against human HSP90β ATPase and 6.6 μM against yeast HSP90β ATPase. This compound induces cell cycle arrest and apoptosis in various tumor cell lines while effectively inhibiting processes such as invasion and angiogenesis. CCT018159 is particularly valuable for research applications in cancer biology and therapeutic development. -
HSP Inhibitor
Cucurbitacin D is a potent HSP90 inhibitor that disrupts the interaction between Hsp90 and co-chaperones Cdc37 and p23. This compound exhibits significant biological activities, including the induction of cell cycle arrest and apoptosis, showcasing its potential as an anti-tumor and anti-inflammatory agent. Cucurbitacin D is useful in research applications aimed at understanding the role of heat shock proteins in cancer and inflammation. -
Hsp70 Inhibitor
JG-231 is an allosteric inhibitor targeting heat shock protein 70 (Hsp70). By disrupting the interaction between Hsp70 and BAG family proteins, JG-231 exhibits an inhibition constant (Ki) of 0.11 μM. This compound effectively inhibits tumor cell proliferation and induces apoptosis, demonstrating significant antitumor activity. JG-231 is valuable for research into the roles of Hsp70 in cancer biology and its potential as a therapeutic target. -
HSP90 C-terminal Inhibitor
NCT-58 is a potent C-terminal inhibitor of HSP90, which effectively disrupts the chaperone’s function without inducing the heat shock response. This compound exhibits significant anti-tumor activity by simultaneously downregulating HER family members and inhibiting Akt phosphorylation. Additionally, NCT-58 demonstrates the capability to kill trastuzumab-resistant breast cancer stem-like cells and induces apoptosis in HER2-positive breast cancer cells, making it a valuable tool for research on cancer therapeutics and resistance mechanisms. -
Hsp70 Inhibitor
YK5 is a potent and selective inhibitor of the heat shock protein 70 (Hsp70). It demonstrates a strong affinity for cytosolic Hsp70s in cancer cells, disrupting the formation of active oncogenic Hsp70/Hsp90/client protein complexes. This biological activity makes YK5 a valuable tool for research applications focused on cancer biology and the study of protein homeostasis in oncogenic processes. -
HSP Synthesis Inhibitor
KNK423 is a specific inhibitor of heat shock protein (HSP) synthesis, targeting HSP70. This compound enhances the efficacy of Amphotericin B against resistant strains of Aspergillus terreus by disrupting HSP expression. KNK423 is valuable for research in cancer therapy and bacterial infection mechanisms. -
FKBP51-Hsp90 Interaction Inhibitor
FKBP51-Hsp90-IN-1 is a selective inhibitor targeting the FKBP51-Hsp90 protein-protein interaction, exhibiting an IC50 value of 0.1 μM against FKBP51. This compound is valuable for research into stress-related diseases, Alzheimer's disease, and various metabolic disorders, owing to its ability to modulate protein interactions critical for cellular stress responses and stability. Its specificity makes it a potent tool for elucidating the role of FKBP51 in disease mechanisms. -
HSP90 Inhibitor
HSP90-IN-20 is a potent inhibitor of Heat Shock Protein 90 (HSP90) with an IC50 of ≤10 μM. This compound plays a significant role in cancer research by impeding the function of HSP90, which is critical for the stability and activity of several oncogenic proteins. HSP90-IN-20 can be utilized to investigate the therapeutic potential of HSP90 inhibition in various cancer models. -
HSP90 Inhibitor
Hsp90-IN-17 is a selective inhibitor of Heat Shock Protein 90 (HSP90) that interferes with its chaperone activity. This compound demonstrates significant potential in addressing various proliferative conditions, including cancer and neurodegenerative disorders. Hsp90-IN-17 serves as a valuable tool for research focused on the molecular mechanisms of HSP90 and its role in disease progression and treatment responses. -
HSP90 Inhibitor
Aminohexylgeldanamycin hydrochloride is a potent inhibitor of Heat Shock Protein 90 (HSP90). This Geldanamycin derivative demonstrates significant antiangiogenic and antitumor activities, making it valuable for cancer research. Its ability to modulate HSP90 function provides insights into the molecular mechanisms of tumorigenesis and offers potential therapeutic applications in oncology. -
SIRT2/Hsp70 Inhibitor
YM-08 is a selective inhibitor of SIRT2 and Hsp70, exhibiting an IC50 of 19.9 μM for SIRT2. This compound effectively penetrates the blood-brain barrier, making it a valuable tool for studying neurodegenerative diseases and cellular stress responses. Its dual inhibitory activity allows for investigation into SIRT2 and Hsp70's roles in various biological processes and potential therapeutic applications. -
HSP70 Inhibitor
DMT003096 is a selective inhibitor of HSP70, a heat shock protein that plays a critical role in cellular stress responses. Its upregulation has been associated with various cancers, including breast, lung, colon, and cervical cancer. This compound is valuable for research applications targeting cancer therapies and investigating the role of HSP70 in tumor progression and survival mechanisms. -
Hsp90 Inhibitor
Hsp90-IN-40 is a specific inhibitor targeting the C-terminal domain of heat shock protein 90 (Hsp90). It demonstrates significant antiproliferative activity against breast cancer cell lines SKBr3 and MCF-7, with IC50 values of 2.57 µM and 2.43 µM, respectively. By disrupting the function of Hsp90, Hsp90-IN-40 promotes the degradation of Hsp90-dependent proteins, thereby inhibiting cancer cell growth. This compound is valuable for research applications focusing on breast cancer therapeutics and mechanisms of Hsp90 inhibition. -
HSP90 Inhibitor
STA-1474 is a potent and selective inhibitor of Heat Shock Protein 90 (HSP90), primarily functioning by disrupting its chaperone activities, which are crucial for the stability and function of numerous oncogenic proteins. This compound induces apoptosis in tumor cells and exhibits significant antitumor efficacy in spontaneous canine cancer models, such as osteosarcoma and thyroid carcinoma. STA-1474 is valuable for research on solid tumors, including osteosarcoma and breast cancer, and offers insights into the role of HSP90 in cancer biology. -
Hsp90 Inhibitor
Hsp90-IN-15 is a potent Hsp90 inhibitor that exhibits significant anticancer activity. This compound promotes apoptosis in cancer cells and effectively induces cell cycle arrest at the S phase. Hsp90-IN-15 also reduces the expression levels of Hsp90 in HeLa cells, making it a valuable tool for research into cancer therapies targeting the Hsp90 chaperone pathway. -
HSP90 Inhibitor
Hsp90-IN-38 is a potent inhibitor of heat shock protein 90 (HSP90), displaying a strong binding affinity with a dissociation constant (Kd) of 87 nM. This compound effectively inhibits HSP90 ATPase activity, with an IC50 of 0.13 μM. Biological activity has been demonstrated in various cancer cell lines, including HCT116, MCF-7, SKBr3, K562, and A549, with reported IC50 values of 0.187, 0.072, 0.105, 0.403, and 0.31 μM, respectively. Hsp90-IN-38 serves as a valuable tool for research into cancer biology and HSP90-related pathways. -
Hsp90 Inhibitor
PU-20F is a potent Hsp90 inhibitor characterized by an EC50 value of 6.8 μM. This compound competes with Geldanamycin for binding to Hsp90, effectively regulating the activity of this crucial molecular chaperone. PU-20F promotes the degradation of the oncogenic Her2 tyrosine kinase and has demonstrated the ability to inhibit the proliferation of breast cancer cells. It serves as a valuable tool for research focused on breast cancer biology and therapeutic strategies. -
Hsp90β Inhibitor
KUNB106 is a selective inhibitor of Hsp90β, demonstrating binding affinities (KDs) of 91 nM for Hsp90β and 38 μM for Hsp90α. This compound exhibits notable antiproliferative activity against various cancer cell lines, including MDA-MB-231, A549, and SKOV-3, making it a valuable tool for studying triple negative breast cancer. KUNB106's selective inhibition of Hsp90β highlights its potential in oncology research focused on targeted therapies. -
Hsp90 Inhibitor
PU3 is an Hsp90 inhibitor that targets the conserved ATP/ADP pocket of the Hsp90 protein, competing effectively with geldanamycin and other compounds. This reagent has been shown to induce the degradation of key oncogenic proteins like Her2, subsequently inhibiting breast cancer cell proliferation through mechanisms such as retinoblastoma protein hypophosphorylation, G1 phase cell cycle arrest, and differentiation. PU3 presents a promising avenue for cancer research, particularly in the context of targeted cancer therapies. -
HSP70/SIRT2 Inhibitor
HSP70/SIRT2-IN-2 is a dual inhibitor targeting SIRT2 and HSP70, demonstrating an IC50 of 45.1±5.0 μM for SIRT2. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Its ability to simultaneously inhibit these two proteins positions HSP70/SIRT2-IN-2 as a useful candidate for studies focused on tumor progression and potential therapeutic strategies. -
HSP Inhibitor
BMS-358233 is a small molecule inhibitor targeting heat shock protein 90 (Hsp90). By competing with geldanamycin, BMS-358233 induces the degradation of various proteins, including HER2, leading to the inhibition of breast cancer cell growth. This compound causes hypophosphorylation of the retinoblastoma protein, resulting in G1 phase cell cycle arrest and differentiation. BMS-358233 represents a novel class of synthetic Hsp90 inhibitors, offering potential therapeutic strategies for treating various cancers. -
Hsp90 Inhibitor
Flavokawain 1i is a potent Hsp90 inhibitor, targeting the heat shock protein 90, which plays a critical role in protein folding and stability. This compound demonstrates significant anti-cell proliferation activity, making it a valuable tool in cancer research. Its ability to disrupt Hsp90 function can provide insights into cancer cell growth mechanisms and therapeutic strategies. -
Cathepsin D/HSP90 Inhibitor
Tasiamide B is a potent inhibitor of Cathepsin D and HSP90, derived from the marine cyanobacteria Symploca sp. This linear peptide serves as a valuable scaffold for the development of inhibitors targeting aspartic proteases. Tasiamide B has demonstrated significant efficacy in skin cancer studies by effectively interacting with HSP90, highlighting its potential in cancer research and therapeutic applications. -
HSP90 Inhibitor
17-DMAP-GA is a potent inhibitor of Heat Shock Protein 90 (HSP90), derived from the Geldanamycin structure. This compound disrupts HSP90's chaperone function, leading to cell cycle abnormalities and apoptosis in cancer cells. It is utilized in research to study the role of HSP90 in tumorigenesis and to explore therapeutic strategies in cancer treatment. -
HSPA5 Inhibitor
HM03 trihydrochloride is a selective inhibitor of HSPA5 (Heat shock 70kDa protein 5, also known as Bip or Grp78). It exhibits potent anticancer activity, making it a valuable tool for research in cancer biology. This compound facilitates the exploration of HSPA5's role in cellular stress responses and its implications in tumor progression and treatment resistance. -
Hsp90 Inhibitor
HSP90-IN-32 is a selective inhibitor of the C-terminal domain of heat shock protein 90 (Hsp90). It exhibits significant anti-proliferative effects in various melanoma cell lines, including SKMel173, SKMel103, SKMel19, and A375, with IC50 values of 1.01 μM, 0.782 μM, 0.607 μM, and 1.413 μM, respectively. This compound holds potential for research focused on developing novel anti-cancer therapeutics targeting Hsp90. -
HSP90 Inhibitor
Hsp90-IN-39 is a selective inhibitor of the HSP90α isoform. This compound exhibits significant antiproliferative activity across multiple cancer cell lines, including MCF-7, HCT116, SKBr3, K562, and A549. Hsp90-IN-39 is a valuable tool for cancer research, providing insights into HSP90-related pathways and therapeutic potential in oncology. -
HSP90/MAO-A inhibitor
MAO A/HSP90-IN-2 is a dual inhibitor targeting HSP90 and MAO A, exhibiting IC50 values of 0.016 μM and 4.58 μM, respectively. This compound enhances HSP70 expression while concurrently decreasing HER2, phospho-Akt, and IFN-γ induced PD-L1 levels in GL26 cells. It effectively inhibits the growth of both Temozolomide-sensitive and resistant glioblastoma cells, alongside other cancer types such as colon cancer, leukemia, and non-small cell lung cancer. MAO A/HSP90-IN-2 shows promise in addressing tumor immune evasion, making it a valuable tool for cancer research. -
Hsp90 Inhibitor
Hsp90-IN-44 is a selective Hsp90 inhibitor with an IC50 of 9.8 µM. This compound demonstrates significant inhibitory activity, making it a valuable tool for cancer research. Hsp90-IN-44 can be utilized in studies aimed at understanding Hsp90's role in oncogenesis and evaluating potential therapeutic strategies targeting this chaperone protein.
